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ABSTRACT 
CIRCULATING IMMUNE COMPLEXES IN SYSTEMIC LUPUS ERYTHEMATOSUS: 
A SEARCH FOR THE ANTIGEN 
Mark Stein 
1984 
In this study I have examined the composition of cryoprecipitates 
obtained from the sera of patients with systemic lupus erythematosus 
and normal donors and sought to determine whether these precipitates 
contain immune complexes which have small nuclear ribonucleoprotein as 
antigen component. I found that the cryoprecipitable protein in serum 
rapidly precipitated when sera were made to contain 3% polyethylene 
glycol. PEG fractions of normal sera and SLE sera were identical 
except that the SLE precipitates contained greater amounts of 
immunoglobulin G and IgM, and proteins with molecular weights between 
80K and 60K, and 30K and 20K. Double immunodiffusion demonstrated 
that both normal and SLE sera contained IgM, C2, C3 and C4, but 
fibrinogen, ceruloplasmin and C5 were not detected. 
Using a DNA probe complementary to the U1 small RNA I searched 
for snRNP immune complexes in SLE sera. Sera was obtained from four 
patients with SLE who were known to have anti-RNP or anti-Sm 
antibodies (both antibodies precipitate the U1 small RNA) while their 
disease was in its quiescent phase. The U1 small RNA was not 
detectable in immune complexes isolated from these patients. 
These findings further expand our knowledge about the composition 
of cryoglobulins and suggest that cryoprecipitation is due to the 
increased concentration of one or more normal serum proteins. The U1 
ribonucleoprotein particle which is a major target for the autoimmune 
response in SLE does not appear to participate in the formation of 
circulating immune complexes. 
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I. ABBREVIATIONS USED 
ANA antinuclear antibody 
°C degree centrigade 
CIg cryoimmune globulin 
cm centimeter 
DNA deoxyribonucleic acid 
dsDNA double stranded DNA 
dsRNA double stranded RNA 
ENA extractible nuclear antigen 
°F degree Fahrenheit 
g gravity 
hnRNA heterogeneous nuclear RNA 
hr hour 
IgG,M,A,E immunoglobulin G,M,A,E 
M molar 





mRNA messenger RNA 
MW molecular weight 
NBPC nitrobenzyloxymethylpyridinium chloride 
PBS phosphate buffered saline 
PCA phenol-chloroform-isoamylalcohol 
Pg picograms 
RBC red blood cell 
RNA ribonucleic acid 
RNP ribonucleoprotein 
rpm rotations per minute 
rRNA ribosomal RNA 
SDS sodium dodecyl sulphate 
SLE systemic lupus erythematosus 
snRNP small nuclear RNP 
ssDNA single stranded DNA 









II. REVIEW OF LITERATURE 
A. Introduction 
Systemic lupus erythematosus (SLE) is a disease of unknown etiology 
that is characterized by inflammatory lesions involving multiple organ 
systems and multiple immunologic abnormalities (1,2). SLE has a 
prevalence of 1 per 1,000 population (3) and an incidence of 1 in 
15,000 population (2). It occurs three times more frequently in 
blacks than in whites and is 10 times more common in females than in 
males (4). The peak age of onset is between 15 and 25 years. 
The typical patient with SLE initially presents with fatigue 
(95%), fever (80%), arthralgia (90%) and a skin rash (15%) (1,4). 
With the disease in its advanced stages the vital organs most often 
involved are kidneys (55%), lungs (45/6), heart (45%), gastrointestinal 
tract (40^) and the brain (30^) (1). Much of the tissue injury in SLE 
results from the deposition of immune complexes. 
When immune complexes are deposited, complement becomes 
activated. Phagocytic cells are attracted and phagocytosis is 
stimulated. Phagocytosis results in the release of lysosomal enzymes 
and other cellular products which results in tissue injury. The immune 
complexes which form in SLE primarily involve autoantibodies. Why the 
immune system should lose tolerance to self antigens is not fully 
understood but several explanations have been proposed. Normally, Ts 
cells downregulate the response of the immune system. This loss of 
tolerance may be due to the loss of suppressor T lymphocytes (5). 
Several factors may lead to the loss of Ts cells. There is a strong 
case for a genetic component. The HLA markers DRW2 and DRW3 are found 
more frequently among SLE patients than the population at large (6). 
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There is a 60$ concordance rate of SLE in identical twins (7). SLE 
patients have a higher incidence of other immune system disorders than 
the population (8). All these examples point to a genetically linked 
cause. 
A second possible cause for the autoimmune phenomenon is a viral 
infection. Viral nucleocapsids are frequently found in endothelial 
cells of SLE patients. Although no specific virus has been 
implicated, antibody titers to various viruses are often elevated in 
lupus sera. Lastly, several DNA and RNA viruses have been identified 
which can induce a lupus like syndrome in laboratory animals (9,10). 
B. Antigens and Antibodies in SLE 
In the sera of lupus patients, autoantibodies have been found 
against the cellular components listed below (11-13). Clinically, 
antigen-antibody complexes based on DNA are especially significant as 
they are the type of immune complexes most often found in deposits 
around basement membranes of the various organ systems (14). It is 
therefore thought that such complexes are responsible for much of the 
pathogenesis of lupus and thus they have been studied extensively. 





















The first laboratory finding characteristic of SLE was reported 
by Hargraves and colleagues at the Mayo Clinic (15). They described 
the appearance of swollen bodies in the cytoplasm of polymorphonuclear 
leukocytes found in the bone marrow of a patient with SLE and called 
these unusual polys "LE" cells. The swollen bodies stained with 
Feulgen reagent and so it was thought that they represented 
phagocytized nuclei or nucleic acid. By 1957 it was known that LE 
cells could be experimentally produced by incubating damaged cells 
with SLE serum containing polys. Holman and Kunkel then showed that 
by preincubating SLE serum with cell nuclei the serum loses its 
ability to induce the formation of LE cells (16). Furthermore, when 
slides containing LE cells were reacted with fluorescent rabbit 
antiserum to human gammaglobulin the inclusion bodies of LE cells 
fluoresced brilliantly. From this evidence they correctly reasoned 
that SLE serum contains antibodies directed against nuclear DNA. When 
the antibody-coated DNA is phagocytized by polys, LE cells are formed. 
The LE cell phenomenon thus became the first study of antinuclear 
antibodies (ANAs). Parallel work on different ANAs was performed in 
the mid-fifties by Seligman and others (16-20). These attempts 
involved use of double immunodiffusion or fluorescent antibody 
techniques to detect reactions between lupus sera and various cellular 
components. Most commonly, the antibodies reacted with DNA. 
Unfortunately, these studies were criticized on the grounds that they 
failed to differentiate between a reaction with naked DNA as opposed 
to one with DNA associated proteins (21,22). Later work overcame this 
problem by showing that the reaction no longer took place if the 
sample was first treated with DNase (22). This showed that DNA 
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comprised either the entire antigenic site or was a necessary 
component of the antigenic site. As immunochemical techniques became 
more sensitive and specific, the true nature of nuclear antigens came 
to light. 
There are essentially three types of anti-DNA antibodies; those 
which recognize ssDNA only, those which recognize native DNA only and 
those which recognize both ssDNA and nDNA (19,23-27). Anti-ssDNA 
antibodies react with determinants hidden in the native molecule. 
Although the exact nature of the antigenic site is not known, Stollar 
et al. believe that the antibodies are reacting with purine bases 
(24,28). They base this conclusion on the observation that purine 
bases or the denatured end products of DNase digest inhibit the 
binding of these antibodies to ssDNA. Native DNA does not inhibit 
this binding. 
The second type of anti-DNA antibodies recognize determinants 
common to both ssDNA and nDNA. Again, the exact nature of the 
antigenic site is not known, but complement fixation studies indicate 
that it is a small, repeating unit —• possibly deoxyribose (23,26). 
The third type of anti-DNA antibody binds exclusively to native DNA. 
The antigenic site in this case is thought to be constituted by the 
tertiary structural feature of the double helix (26). Not all 
researchers share this view. They cite evidence which shows that 
ssDNA, when present in high concentrations, inhibits the binding of 
these antibodies to nDNA. Others argue that this inhibition is due to 
the recombination of two ssDNA chains. 
Most of the early studies centered around DNA as the most 
important reactive nuclear antigen. This was partly due to the 

6 
simplicity of isolation of DNA. When nuclei are disrupted in isotonic 
saline, deoxyribonucleohistone is easily recovered as a precipitate 
(29). In his search for an SLE antigen other than DNA, Holman 
disrupted nuclei in saline, discarded the precipitated DNA and 
recovered the supernatant. When this supernatant was saturated with 
ethanol at room temperature a precipitate formed which, like nucleic 
acid, bound to antibodies from SLE serum. Since it was extracted from 
the supernatant, Halman called it an extractible nuclear antigen 
(ENA). This ENA was found to be composed of acidic, non-histone 
proteins and RNA and so it is also called ribonucleoprotein (RNP) 
(29). Unlike DNA and nucleoprotein, RNP is insensitive to digestion 
by DNase and trypsin. It is nondialyzable and is stable between pH's 
5 and 9 and at temperatures less than 56°C. One year after Holman's 
discovery, Tan and Kunkel described a second ENA (30). The sera used 
to detect this antigen came from a patient with the last name of Smith 
and it was thus called Sm. In addition to being resistant to DNase 
and trypsin, Sm is also resistant to digestion by RNase. Sm and RNP 
are also referred to as small nuclear ribonucleoproteins (snRNP). 
Each has a molecular weight less than 150,000 and a sedimentation 
coefficient of 7S. When bound to antibodies, each can fix complement 
(29,30). 
The molecular identity of the antigen recognized by anti-RNP and 
anti-Sm antibodies finally became apparent when Lerner and Steitz 
developed a new assay based on immunoprecipitation of extracts of ^2p 
labeled HeLa cells. In this assay 32P is first incorporated into the 
cell's RNA. The cells are then disrupted by sonication. This 
releases the labeled snRNPs and other molecules containing nucleic 
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acids into the supernatant. The snRNPs are bound to anti-Sm and anti- 
RNP antibodies from SLE sera and the resulting immune complexes 
precipitated with staphylococcal protein A. Since snRNPs were thought 
to be composed of RNA and protein, Lerner and Steitz examined these 
components separately. 
In their protocol, the RNA part is recovered from the immune 
complexes by extraction with phenol-chloroform. The RNA is separated 
on a urea-acrylamide gel and the location of these bands compared to 
known RNA species (31). Anti-RNP precipitated only one band of RNA 
which is called U1 (see Figure 1). Anti-Sm precipitated 5 bands, 
labeled U1-U6. These RNAs turned out to be a previously studied snRNA 
species whose importance and function was not previously appreciated. 
U1-U6 have since been fully sequenced and range in size from 100 to 
200 bases. 
To study the protein portion of snRNPs, HeLa cells were first 
labeled with ^S-methionine. 35s is incorporated in all newly 
synthesized proteins including the protein portion of snRNPs. Again, 
snRNPs are precipitated with SLE sera, adsorbed to a staph protein A- 
sepharose column and then eluted from this column. This procedure 
separates immune complexes from other proteins. The purified 
complexes are then fractionated on an SDS-acrylamide gel. It was found 
that anti-Sm and anti-RNP antibodies can bind to the same seven 
proteins. The molecular weights of these proteins range from 12,000 
to 35,000 Daltons. Each snRNP contains only one snRNA species. The 
U1 snRNP complex is composed of the U1 snRNA and all seven proteins. 
snRNPs containing the other U RNAs are composed of the respective RNA 
and a subset of any five of the seven proteins (25,31,32). 
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An intact snRNP complex is required for antigenicity. Neither 
anti-Sm nor anti-RNP can precipitate snRNAs after deproteinization. 
Likewise, the protein portion of snRNPs cannot be precipitated after 
the snRNA has been removed (33-35). 
C. Role of snRNPs 
Although one gene codes for one polypeptide chain, many 
eukaryotic genes occur in pieces. Within the genome, the 
informational DNA sequences may be interrupted numerous times by 
extraneous segments of DNA. These intervening segments are known as 
introns while the segments bearing information are called exons. The 
ends of an intron attached to the exon segments are called splice 
junctions The entire gene, including both introns and exons, is 
initially transcribed to heterogenous nuclear RNA. The hnRNA 
is then processed. The introns are cut out and the exons are spliced 
together to form the final message. Whereas the base sequence of 
introns vary, the sequence of splice junctions is essentially 
identical from gene to gene (36). 
The mechanism involved in splicing is unknown. Recently, Lerner, 
Steitz and others proposed that snRNPs are intimately involved in this 
process (37,38). They reason that several conditions would have to be 
met for their proposal to be valid. From an evolutionary standpoint, 
higher eukaryotic species possessing interchangeable transcription 
systems should also possess the same splicing mechanism. Therefore, 
the structure of snRNPs should be highly conserved across different 
species if they are to mediate splicing. snRNPs from man, frogs, 
mouse, rat, chicken and sea urchins can all be precipitated by SLE 
serum indicating that they are antigenically similar. When sequenced, 
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the snRNA from all these species are either highly similar or 
completely identical to human snRNA (31,37,39,40). 
Also, if the theory is correct metabolically active cells should 
have a higher concentration of snRNPs than inactive cells. In 
relative terms, liver cells and erythroblasts can be considered 
metabolically active and mature red blood cells inactive. Studies 
have shown that liver cells have a 25-fold increase in snRNPs over red 
blood cells. When the percent of the erythroblast component of blood 
is increased the above ratio is decreased (37,41). 
Further evidence for the theory could be found by showing that 
removal of snRNPs blocks the splicing process and thus retards the 
formation of mRNA. Indeed, the addition of anti-Sm or anti-RNP 
antibodies to a cell free splicing system will block the formation of 
mRNA (42). This shows that splicing is dependent on the presence of 
snRNPs. 
The most stringent condition that needs to be met is that snRNPs 
should be able to recognize and bind to splice junctions since this 
would be necessary to facilitate the splicing mechanism. The sequence 
of both the 5’ and 3' ends of U1 snRNAs are conserved and highly 
complementary to the base sequence of splice junctions (37,38). Thus, 
the snRNP complex can both bind to splice junctions and participate in 
the splicing mechanism. Whether snRNPs serve only to align the 
splice junctions or also to enzymatically cut out the introns is not 
known. The function of the other U snRNAs is not yet known but there 
is growing evidence that they too are involved in the transcription 
and translation processes (43). 
Much less is known about two other ribonucleoproteins, La and Ro 
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(44-46,79)* Early cell fractionation and immunofluorescence studies 
indicated that Ro and La were cytoplasmic in origin (45). More recent 
studies have demonstrated the antigenic identity of Ro to SS-A, and La 
to SS-B. SS-A and SS-B are two nuclear antigens extracted from Wi^ 
cells, a lymphoblastoid cell line (44,47,49). La is sensitive to 
trypsin and both La and Ro are sensitive to ribonuclease. They show 
many physical similarities to Sm and RNP but do not contain the same 
snRNA species (Figure 1). 
D. Significance of Antinuclear Antibodies 
Antinuclear antibodies are often found in the serum of patients 
with SLE and other rheumatic diseases. While not present in every 
individual, nor found exclusively in any one disease, certain ANAs are 
thought to be characteristic of particular illnesses (Table 1). 
Antibodies to ssDNA and dsDNA are found in 50-60% of all lupus 
patients. Those against histones and RNP are found in 25-40%. Anti- 
La is found in 10-15% and anti-Ro in 30-40% of SLE patients (27). 
While Sm antibodies are present in only one third of SLE patients, 
they are considered pathognomonic for lupus since they do not exist in 
the sera of patients with other connective tissue diseases (48). 
However, the most important point to consider is not the presence of 
any one specific antibody, but rather the wide spectrum of ANAs 
present in lupus. For example, although anti-RNP is present in nearly 
100% of patients with mixed connective tissue disease (MCTD), they are not 
diagnostically significant since anti-RNP is also found in patients 
with lupus and other rheumatic diseases. What is important is that 
the only other ANA present in MCTD is anti-ssDNA. Therefore, lupus 
can be easily distinguished from MCTD because of the higher 

variability of ANAs in the sera of lupus patients. Diagnostically, 
therefore, the spectrum of antibodies can be more important than the 
presence of a specific antibody. One possible exception to this rule 
is found in patients with neonatal lupus. Nearly all infants and 
their mothers have antibodies to only the Ro antigen (49-51). 
The serum antigen or antibody concentration often correlates with 
the severity of the disease. For example, in one patient with SLE, 
recurrent bouts of very high fever, skin rash and proteinuria 
coincided with the appearance of DNA in his serum and resolved with 
the appearance of anti-DNA antibodies (12). High titers of anti-RNP 
without elevation of anti-Sm is not predictive of the activity of SLE, 
although it does correlate with the severity of MCTD (52-55). The 
presence of RNP antibodies in children with lupus is a poor prognostic 
sign usually indicating renal and cardiac involvement and a high 
fatality rate. In MCTD, high titers of anti-Ro are associated with 
polyarthralgia (90$), Raynaud's phenomenon (81$), 
hypergammaglobulinemia (74$), polyarthritis (74$), swollen hands 
(73$), esophageal hypomotility (58$), sclerodactyly (50$) and myositis 
(50$) (56,57). 
Research correlating Sm to the severity of SLE shows mixed 
results. Winn found that patients with Sm antibody and no DNA 
antibodies have a milder form of lupus than patients who also possess 
DNA antibodies (58,80). In the latter group of patients, 
hypertension, central nervous system disease and renal disease 
occurred less frequently. Specifically, on renal biopsy only 1/23 
patients with Sm antibodies alone had diffuse proliferative 
glomerulonephritis whereas this was true for 6/14 patients who also 
had DNA antibodies. From this evidence it can be concluded that the 
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level of antibody or antigen in a patient's serum often correlates to 
the severity of a specific disease. Some of the mechanisms for this 
phenomenon have been mentioned; others have yet to be discovered. 
E. The Property of Cryoprecipitability 
In 1946 Lerner first described a group of proteins that 
precipitated from cooled serum and named them cryoglobulins (59,60). 
The major protein component of this mixture was separated and found to 
have many physical properties similar to gamma-globulin. Since that 
time, cryoglobulinemia was found to be associated with many disease 
processes. Due to their immunochemical diversity, cryoglobulins have 
been classified into three groups by Bonet et al. (61). Type I are 
composed of isolated monoclonal immunoglobulin: either IgM, IgG, IgA 
or Bence-Jones protein. Type II cryoglobulins are mixed cryoglobulins 
with a monoclonal component possessing antibody activity against 
polyclonal IgG. Type III cryoglobulins are mixed polyclonal 
immunoglobulins or nonimmunoglobulin molecules. This last type of 
cryoglobulin is predominantly present in inflammatory and autoimmune 
diseases such as lupus erythematosus. 
Many theories have been put forward to explain 
cryoprecipitability. Lerner originally hypothesized that this 
property derived from modified gamma-globulins but could not determine 
what the modification was (59). His hypothesis represents the 
classical theory of cryoprecipitation although it applies more to Type 
I and II cryoglobulins than Type III. Many researchers have expanded 
on his theory. 
Levo proposes that cryoprecipitation is due to immunoglobulins 
which differ from normal by lacking sialic acid or other carbohydrate 
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residues. Removal of these residues leads to decreased solubility of 
immunoglobulins. Levo based his hypothesis on the results of chemical 
analysis of immunoglobulin side chains obtained from the sera of 
patients with cryoglobulinemia. Humans possess three kinds of 
immunoglobulins: intracellular, membranous and secretory. The 
secretory kind is found in blood and differs from the intracellular 
kind in the amount of carbohydrate residues that it possesses. This 
glycosylation is a post-transcriptional event (66,67). Some secretory 
immunoglobulin may leak out of B cells before glycosylation has had a 
chance to take place. This is evidenced by the fact that healthy 
people contain small amounts of cryoprecipitable immunoglobulins in 
their blood. Infectious, malignant and autoimmune diseases are often 
characterized by the intense stimulation of the lymphoreticular 
system. The glycosylation process may not be able to keep up with 
this increased protein synthesis rate and so intracellular 
immunoglobulins will leak out at a faster rate. This, Levo 
hypothesizes, causes the accompanying increase in cryoglobulin 
formation. 
A different explanation, but one that is also based on the 
decreased solubility of modified immunoglobulins, was proposed by 
Erickson et al. (68). They feel that the modification lies in the 
primary structure of the heavy chain variable regions of 
immunoglobulins. Point mutations cause different amino acids with 
different side chains to be inserted in this region in place of the 
normal amino acids. These novel side chains when directed either 
inwardly or outwardly, disturb the normal hydrophobic interactions and 
change the folding pattern of adjacent segments of the protein. The 

immunoglobulin then assumes a configuration which is less soluble at 
low temperatures. They reached this conclusion by sequencing the 
heavy chain variable regions of monoclonal immunoglobulins obtained 
from two patients with cryoglobulinemia. Both samples of 
immunoglobulins contained extra residues in the outer beta sheet 
structure of the domain which on metric analysis were shown to 
alter internal and external hydrophobic interactions. 
Christian et al. believe that the property of cryoprecipitability 
is dependent on a heat labile serum factor (69). In their study, SLE 
sera was first measured for its ability to form cryoprecipitates. The 
sera was then heated to 56°C and it was noted that this significantly 
decreased the amount of precipitate which was later able to form. 
The researchers concluded that a heat labile serum factor must play a 
crucial role in initiating cryoprecipitation. By adding back various 
serum fractions, each enriched in one specific protein, they identified 
Cl and an 11s component of complement as two factors which could 
restore cryoprecipitability. 
Yet another protein which has been implicated in 
cryoprecipitation is cold-insoluble globulin (CIg). Although the identity 
of CIg is not definitively known, its structure is believed to be a 
two-chain dimer covalently bounded by disulfide bridges and folded 
into a beta-structure (70-72). CIg causes cryoprecipitation by 
forming complexes with fibrin-fibrinogen. These complexes are 
temperature dependent; forming in the cold and separating at body 
temperature (73) 
Some researchers feel that CIg is identical to the protein 
fibronectin. They base this conclusion on the observation that the 
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two proteins have similar structures and are antigenically identical 
(74). Like CIg, fibronectin also forms insoluble complexes with 
fibrin-fibrinogen. In recent studies linking fibronectin to 
cryoprecipitation, fibronectin has been found in cryoprecipitates from 
synovial fluid of five of five rheumatoid arthritis patients and from 
the sera of two of two SLE patients (75,76). In these studies, 
removing fibronectin reduced the amount of cryoprecipitable material. 
Hardin also suggests a model in which cryoprecipitability is a 
property of large normal serum proteins and not of the immune 
complexes themselves (77). In one set of experiments, normal non¬ 
immunoglobulin proteins were precipitated from normal sera with 
polyethylene glycol. These proteins had the property of precipitating 
spontaneously at 4°C and resolubilizing at 37°C. Experimentally 
produced, cold soluble antigen-antibody complexes were made and mixed 
with the cryoglobulins. When incubated at 4°C, the normal, cold 
insoluble serum proteins were able to co-precipitate the immune 
complexes. Thus, large serum proteins were shown to act as 
cryoprecipitagogues, co-precipitating the immune complexes. Another 
line of evidence supporting non-immunoglobulin induced 
cryoprecipitation is that sera from some patients can form 
cryoprecipitates even though they do not contain any circulating 
immune complexes as measured by the ^-’I-Clq binding assay (78). 
Two explanations (which are not mutually exclusive) for 
nonimmunoglobulin induced cryoprecipitation have been proposed. The 
first, as has been mentioned previously, is that fibronectin binds to 
cold-soluble fibrin-fibrinogen complexes to form cold-insoluble 
complexes. Fibronectin can be found in both PEG fractions of normal 
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sera and in cryoglobulin isolated from patient serum (75-77). The 
second explanation is that cryoprecipitation is due to a normal 
concentration effect. In many disease states the serum concentration 
of large proteins normally increases. Intermolecular interactions 
become more pronounced and this in turn leads to decreased solubility 
in the cold. Thus, this theory is very simple and elegant in that it 
does not call on special protein interactions or changes in protein 
structure. 
The non-immunoglobulin portion of cryoprecipitates has never been 
systematically studied. However, in the course of research done to 
identify the mechanism of cryoprecipitation, a number of proteins have 
been identified. These are: Cl and 11s component of complement (69), 
fibronectin (74-77), beta-|A and lipoprotein (61), and fibrin and 
fibrinogen (73). It must be cautioned that not all of these proteins 
were reported to be present by every investigator. 
F. Purpose of this Thesis 
Two broad goals guided the work of this thesis. My first 
objective was to determine whether the sera of patients with SLE 
contain immune complexes which have small nuclear ribonucleoprotein as 
the antigen component. As has been discussed, patients with lupus 
produce antibodies which bind to specific snRNPs _in vitro. The level 
of these antibodies often correlates to the activity of the disease 
and for this reason it is often clinically useful to monitor anti- 
snRNP levels. Likewise, the presence of snRNP immune complexes may 
also have prognostic and therapeutic implications. As Tan and 
colleagues pointed out, the onset of an acute flare in an SLE patient 
was heralded by an increase in the DNA antigen whereas a remission was 
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preceded by an increase in DNA immune complexes (12). Since much of 
the pathogenesis of SLE is due to the deposition of immune complexes 
it may prove clinically important to ascertain the presence or absence 
of snRNP immune complexes in various end organs. Thus far the search 
for these complexes has been hampered by the lack of a sensitive 
technique with which to detect them. Recently, with the cloning of 
the U1 gene and the development of hybridization techniques, a 
powerful method for identifying the presence of snRNP immune complexes 
has become available and has made the study of this problem possible. 
My second goal was to examine the composition of cryoprecipitates 
from normal and SLE sera. Although cryoglobulins have been studied 
extensively over the past 25 years, many fundamental questions remain. 
We still do not fully know the composition of cryoprecipitates or 
understand the mechanism for cryoprecipitation. Determining the 
former may provide an answer to the latter. For example, if it were 
found that the only difference between cryoglobulins from lupus sera 
and those from normal sera was an increase in the concentration of 
immune complexes then this would support the theory that 
cryoprecipitation is due to increased concentration of modified 
immunoglobulins. Likewise, if it was found that the sole difference 
was an increase in the concentration of normal serum proteins, it 
would support that mechanism of cryoprecipitation. For these reasons 
I identified some of the components of cryoglobulins by immunological 




III. MATERIALS AND METHODS 
A. Solutions 
PBS 
0.01M P04 (1.42gm/L) 
0.15M NaCl (8.76gm/L) 
pH 7.4 
PEG (6% or 3%) 
6gm of Polyethylene Glycol M.W. 6,000 in 100ml Borate Buffer 
3gm of Polyethylene Glycol M.W. 6,000 in 100ml Borate Buffer 
Borate Buffer 
0.1M H3B03 (6.I8gm/L) 
0.025M Na2B207*10H20 (9.53gm/L) 
0.075M NaCl (4.38gm/L) 
pH 8.3 
Sucrose Solutions (10%, 40%, 60^) 
lOgm, 40gm or 60gm of sucrose in 100ml of PBS 
NET Buffer 
50mM Tris (6.05gm/L) 
150mM NaCl (8.7gm/L) 
pH 7.5 
NET-1 
O.gm NP-40 in 100ml NET Buffer 
NET-2 
0.05gm NP-40 in 100ml NET Buffer 
PCA 
Phenol (redistilled) 50ml 
Chloroform 50ml 
Isoamylalcohol 1ml 
8 Hydroxyquinoline 0.1gm 
TBS 
0.05M Tris-HCl (7.9gm/L) 
0.150M NaCl (8.7gm/L) 
pH 7.5 
TBE 
0.1M Tris (12.1Igm/L) 
0.1M Borate (6.l8gm/L) 




Sample Buffer for RNA Electrophoresis 
7M Urea (420g/L) 
0.1% Bromophenol Blue 
0.1% Xylene Cyanol-FF 
dissolved in TBE 
Acetate Buffer 
0.2M NaOAc (I6.4gm/L) 
pH with 0.2M Acetic acid (12ml/L Glacial Acetic Acid) 
pH 4.0 
Solution for Stacker Part of Protein Gels 
I. 6ml of 2M Tris-HCl pH 6.8 
0.5ml of 0.2M EDTA 
0.5ml of 10% SDS 
34ml of H2O 
9ml of 30% Acrylamide 
0.05ml of TEMED 
5ml of Ammonium Persulfate (0.38gm/25ml H^O) 
Solution for Lower Part of Protein Gels 
II. 88ml of 2M Tris-HCl pH 8.8 
0.63ml of 0.2M EDTA 
0.63ml of 10% SDS 
24.38ml of H20 
18.75ml of 30% Acrylamide 
0.06ml of TEMED 
6.25ml of Ammonium Persulfate (0.38gm/25ml H20) 
Running Buffer for Protein Gels (Per 4L Solution) 
Glycine I47gm 
Tris 24.2gm 
0.2M EDTA 40ml 
10% SDS 40ml 
pH 8.6 
2X Sample Buffer for Protein Gels 
61.5 yl of 2M Tris 
400 yl of 10% SDS 
100 yl of B-Mercaptoethanol 
400 yl of Glycerol 
10 yl of 0.5% B-cartoene dye 
28.5 yl of H20 
pH 6.8 
10X NT 
0.5M Tris-HCl (79gm/L) 
0.5M MgCl 
0.1M B-Mercaptoethanol 





50$ Formamide (500ml/L) 
0.9M MaCl (52.6gm/L) 
0.05M EDTA (1.86gm/L) 
0.05M Na2HP04(7.1gm/L) 
0.1$ SDS (Igm/L) 




Salmon Sperm DNA (250 yg/ml), sonicated and denatured 
pH 7.0 
B. Enzymes, Radionucleotides and Reagents 
2'deoxyguanosine 5’triphosphate 
2'deoxythymidine 5'triphosphate 
32p_2* deoxyadenosine 5'triphosphate 
^^P-2'deoxycytidine 5'triphosphate 




Minimal essential medium 





















C. Human Subjects 
5-50ml of blood was obtained from 6 patients and 12 controls 
after obtaining informed consent. The consent consisted of a full 
explanation of the purpose for which the blood specimens will be used 
and the potential risks of venipuncture. All patients were followed 
at the Yale Rheumatology Clinics and had systemic lupus erythematosus 
as defined by the American Rheumatism Association (82). 
D. Composition of Cryoprecipitates 
1. Preparation of Serum. Approximately 100ml of blood was 
obtained by venipuncture from patients and controls and allowed to 
clot at 37°C for 30 min., followed by 30 min. at 4°C. The clots were 
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centrifuged at lOOOg for 10 min. at 4°C in an ICC clinical 
centrifuge. 50ml of serum was recovered from each sample and 
clarified further by re-centrifuging for 10 min. Each was then 
divided into two equal aliquots of 25ml (A^ and A2). 
2. Isolation of Cryoprecipitates. A^ aliquot serum was 
incubated for 48 hr. at 4°C. The precipitate which formed was 
sedimented at 12,000g for 10 min. at 4°C in a Sorvall RC-5B 
centrifuge. The pellet was washed 3 times with 10ml of PBS at 4°C. 
The washing steps were carried out at 12,000g for 10 min. each. The 
thrice washed cryoprecipitate was re-solubilized in 1ml of PBS by 
incubating for 30 min. at 37°C. Any remaining insoluble material was 
removed by centrifugation. The cryoglobulins were allowed to re¬ 
precipitate at 4°C and were stored in this form (77). 
3. Isolation of Putative Cryoprecipitogogues. All steps were 
carried out at 4°C unless otherwise noted. A2 serum was added to an 
equal amount of 6% PEG in Borate buffer and incubated for 1 hr. The 
resulting suspension was sedimented at 12,000g for 10 min. and the 
pellet washed with 3% PEG in Borate buffer. The washed pellet was 
solubilized in 1ml PBS by incubating for 30 min. at 37°C. Any 
insoluble material was removed by centrifugation. The solution 
(containing the putative cryoprecipitogogue) was dialyzed in 1cm 
dialysis tubing for 24 hr. against 6 liters of PBS. The resulting 
precipitate was collected and stored in 1ml of PBS at 4°C (77,83). 
4. Electrophoresis of Cryoprecipitates. Protein 
electrophoresis was carried out using a modified O'Farrell technique 
(86). A 9% acrylamide pH 8.8 gel was used with a 5% acrylamide pH 6.8 
stacker. Gel dimension was 0.8 x 12 x 18cm. Gels ran at 100V for 
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4-6 hr. or at 50V overnight. Sample buffer was prepared at 2X 
concentration and mixed 1:1 (v/v) with the sample solution. This 
mixture was heated to 100°C for 1 min. before loading onto the gel. 
After the run was finished, gels were stained with either Coomassie 
Blue or "Silver Stain III" (87). 
5. Double Immunodiffusion. Double immunodiffusion was performed 
using a modified Ouchterlony and Tan and Kunkel method (30,88) (Figure 
2). agarose in PBS, with 0.1% sodium azide was layered 1mm thick 
on glass microscope slides. The agarose was allowed to harden and 6 
wells were punched out. 10 y1 aliquots of solubilized cryoglobulins 
were placed into wells in the outside ring. The center well contained 
specific antisera. Diffusion was allowed to proceed for 24 hr. before 
reading. 
E. Identification of snRNPs in Circulating Immune Complexes 
1. Detection of Immune Complexes. Immune complexes in patient 
sera were quantified by Dr. John Hardin using the ^5>I-C1q binding 
assay (89). 
2. Isolation of Immune Complexes. Immune complexes were 
isolated by modification of the method previously described. These 
modifications were instituted to decrease the temperature and amount 
of time required for isolation with the goal of decreasing the 
degradation of RNA contained in the snRNP complexes by contaminating 
RNase. Briefly, blood was clotted for 30 min at 0°C. The clot was 
removed by centrifuging once at 1,000g for 10 min. at 0°C. The serum 
was added to an equal volume of 6% PEG in Borate buffer and slowly 
stirred for 1/2 hr. at 0°C. The precipitate was washed once with 3% 
PEG and resuspended in PBS (v/10 starting volume) (83). 
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3. Sucrose Density Gradients. The suspension (1-2ml) was 
layered on a 10%—40% linear sucrose density gradient with a 60% 
sucrose base. Nitrocellulose centrifuge tubes were used and the 
sample spun at 27,000 rpm for 28 hr. at 4°C in a Beckman SW27 rotor. 
At the end of each run, gradient tubes were punctured from the bottom 
and fractions collected dropwise (approximately 1ml per fraction). 
The OD23Q of each fraction was automatically recorded with a Pharmacia 
model UV-1 spectrophotometer which was connected in series with the 
fraction collector. The peak containing immune complexes was pooled 
and used immediately in the next step (77). 
4. Extraction of RNA. The pooled immune complexes were adsorbed 
to Pansorbin, a commercial preparation of staphylococci protein A, 
according to the method of Kessler (90). All steps were carried out 
at 0°C unless otherwise stated. Briefly, 2ml of Pansorbin was 
pelleted by centrifuging in a 10ml Corex tube at 7,000 rpm for 5 min. 
in a SS34 rotor. The pellet was washed once with NET-1 buffer and 
twice with NET-2 buffer. It was then resuspended in 2ml of NET-2 and 
saved up to four days. 100 yl of washed Pansorbin was incubated with 
the immune complex peak for 30 min. This step allows protein A to 
adsorb the immune complexes. The suspension was washed five times 
with NET-2 and resuspended in 400 yl of NET-2. This was then mixed 
with 400 yl of PCA in an Eppendorph tube and allowed to stand at room 
temperature for 25 min. The two-phase mixture was spun for 1 min. in 
a Beckman B microfuge and the aqueous (top) phase removed and saved in 
a new Eppendorph tube. 2 yl of carrier RNA (lOmg/ml) was added along 
with 1.5ml of absolute ethanol. The tube was let stand at -20°C for 
1-2 hr., until all RNA precipitated. The tube was then centrifuged 
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for 5 min., the supernatant poured off and any remaining ethanol 
lyophilized away. 
5. Preparation of known snRNP Immune Complexes. snRNPs were 
isolated from HeLa cells and incubated with anti-Ro, anti-La and anti- 
Sm antisera (3D. All steps were performed at 0°C unless otherwise 
noted. HeLa cells were grown in minimal essential medium to a 
concentration of 4 x 10^ cells/ml. 100ml of cells were sedimented at 
2,000 rpm for 5 min. in a SS34 rotor and the supernatant discarded. 
The pellet was washed with 10ml of TBS and then resuspended in 2ml of 
TBS. The cells were broken by sonication for 3 x 30 sec. at setting 3 
of a Branson sonifier. The suspension was clarified by centrifugation 
at 8,000 rpm for 10 min. and the supernatant retained as the source of 
antigen. 100 yl of antigen was incubated in an Eppendorph tube for 
15 min. with 20 yl of known antisera kindly provided by Dr. John 
Hardin. On completion of the incubation step, 100 yl of washed 
Pansorbin was added and the RNA isolated as described in part 4. 
6. Electrophoresis of RNA. RNA from immune complexes and 
control RNA were dissolved in 30 yl of sample buffer. The samples 
were heated at 60°C for 5 min. to denature the RNA and then loaded 
onto the gel (31). In addition, ^2p labeled RNA standards, kindly 
provided by Dr. Joan Steitz, were run as controls to ensure proper 
transfer to Northern paper. The gel was 0.8 x 10 x 13cm and 10% 
acrylamide-4M urea. It was run at 300V for approximately 4 hr. (until 
the second dye was about to run off). TBE was used as the running 
buffer. Following completion of electrophoresis the gel was washed 
3 x 20 min. with acetate buffer (31). 
7. Northern Transfer. The Northern procedure allows 
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electrophoretically separated nucleic acids to be covalently bound to 
cellulose paper (91). The paper-RNA is used as a solid support for 
hybridization. All steps were carried out in a hood. Whatman 540 
filter paper was cut to 10 x 12cm size and treated with a solution of 
NBPC and sodium acetate (2.3mg nitrobenzyloxymethyl pyridinium 
chloride and 0.7mg sodium acetate in 28.5 yl of water per square 
centimeter of paper) at 60°C for 3-5 min. or until the paper was 
nominally dry. The paper was then more fully dried in a 65°C oven for 
20 min. and then at 135°C for 40 min. It was then washed four times 
with distilled water and three times with acetone. These steps result 
in the covalent linkage of n-nitrobenzyl groups to the cellulose. The 
paper was then incubated at 60°C for 30 min. in 150ml of 20$ (w/v) 
sodium dithionite. It is then washed with water and 30$ acetic acid. 
These steps result in the reduction of the nitro group to an analine 
group. The paper is incubated for 1/2 hr. in ice cold 1.2M HC1 
(0.3ml/cm ) and sodium nitrate solution (2.7ml of lOmg/ml NaN02 
solution per 100ml of HC1 used). This converts the analine group 
into a diazo group that can covalently bind RNA. The transfer itself 
is similar to Southern's. Transfer is carried out overnight at room 
temperature (Figure 3) (91). 
8. Preparation of Radioactive Probe. Plasmid DNA containing the 
U1-RNA gene was kindly provided by Dr. Alan Weiner. 1 yl of DNA (0.4 
yg/ yl) is added to an Eppendorph tube containing 2.5 y 1 of 10X NT 
buffer and 2.5 yl of two nucleotides (10 yM), usually 
2'deoxyguanosine 5'triphosphate and 2'deoxythymidine 5'triphosphate. 
1 yl DNAse (lOOpg freshly diluted from 1 mg/ml) is added and the 
mixture incubated at 25°C for 10 min. (47,92). The DNAse creates 

26 
numerous nicks in the plasmid. 7 yl of ^^P-2'deoxycytidine 5'- 
triphosphate and 2.5 yl (10 units) of DNA polymerase I are added and 
the mixture incubated at 15°C for 1 hr. In this step, the polymerase 
incorporates the hot and cold nucleotides in the spaces where nicks 
were previously created. The reaction is stopped by passing the 
mixture over a 3ml G25 Sephadex column equilibrated with 10mM Tris, pH 
7.0. The first peak contains the radioactive probe which is then used 
for hybridization. 0.5ml fractions were collected from which 5 yl 
aliquots were withdrawn and tested for radioactivity in a Packard 3385 
scintillation counter. 
9. Hybridization. The Northern paper which is now covalently 
bound to the electrophoretically separated RNA is incubated with 15ml 
of hybridization buffer plus 1 % glycine at 42°C for 48 hr. During 
this time, the hybridization vessel is constantly, gently agitated. 
After hybridization, the paper is washed 2 x 15 min. with 250ml of 2X 
SSC buffer plus 0.1$ SDS, and then 2x15 rain, with 250ml of 0.2X SSC 
plus 0.1$ SDS at 45°C (91). 
The paper is blotted dry, covered with Saran Wrap and placed on 





A. Composition of Cryoprecipitates 
1. Comparison of Cryoglobulins to PEG Precipitates. 
Cryoglobulins are serum proteins that precipitate at low temperature. 
Often, only very little precipitate is obtainable from normal serum. 
PEG is known to precipitate immune complexes as well as large amounts 
of other reversibly cryoprcipitable proteins (77,83). Since a large 
supply of cryoglobulins is not easily available, it would be helpful 
to know if PEG cuts could be used as a substitute. For this reason 
the protein composition of PEG cuts was compared to cryoglobulins 
obtained by precipitating in the cold. 
Normal volunteers donated 100ml of blood each, from which 50ml of 
serum was obtained. The sera were divided into two fractions; one 
treated with PEG and the other left at 4°C to allow cryoglobulin to 
precipitate. Three sets of cryoglobulins and three PEG cuts were 
loaded into separate wells in an acrylamie gel (84,85). A lane 
containing five standard proteins of MW 94K, 67K, 43K, 30K and 20K and 
a lane containing IgG and IgM were also included. After completion of 
the run, the gels were stained and photographed. A total of 20 bands 
were visualized in each of the cryoglobulin and PEG lanes. Two of 
these bands clearly corresponded to IgG and IgM. Each band from the 
cryoglobulin samples matched up with a corresponding band from the PEG 
samples. This experiment demonstrates that cryoglobulins and PEG cuts 
of sera are identical in their protein composition (Figure 4). 
The above experiment was repeated, only this time using serum 
from patients with SLE. Again, 20 bands were visualized and there 




2. Differences between Cryoprecipitates from Normal Sera and SLE 
Sera. The differences in cryoprecipitates between normal and SLE sera 
is of great importance. This information will increase our knowledge 
of the mechanism of cryoprecipitation and aid our understanding of the 
pathophysiology of lupus. In the first set of experiments, 
cryoglobulins from SLE and normal sera were compared 
electrophoretically (84,85). 1ml of serum was obtained from four SLE 
patients and four healthy controls. Cryoglobulins were precipitated 
with PEG and each sample loaded onto an acrylamide gel along with a 
mixture of five standard proteins. After running for the appropriate 
time, the gel was stained with Coomassie Blue or Silver Stain III 
(86). As in the previous experiment, 20 bands were visualized in each 
lane. The SLE lanes were identical to the normal cryoglobulin lanes 
in their protein composition. Each protein band from the patient 
samples had a matching counterpart in the control lanes. The protein 
concentration of these samples were, however, markedly different. 
Essentially, there was a generalized increase in concentration of 
proteins from the SLE samples. Specifically, proteins with MW between 
80K and 67K, and 30K and 20K were most markedly increased in 
concentration (Figure 5). This evidence gives further support to the 
theory that cryoprecipitation may be due solely to a concentration 
effect. 
Type III cryoglobulins contain polyclonal immunoglobulins as well 
as numerous serum proteins. Some of these proteins have been 
identified although the majority remain unknown. In order to 
establish the identity of new proteins and confirm previous findings, 
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double immunodiffusion on Ouchterlony plates was performed (30,87). 
1,6 agarose was used and the diffusion allowed to proceed for 24 
hours. Cryoglobulins were obtained from the sera of six patients and 
eight controls and tested against antisera to the following: C^, C^, 
C^, fibrinogen, ceruloplasmin, IgG and whole serum. As expected, 
antisera against IgG and whole serum showed very strong reactions. 
and antisera each precipitated a line of identity with 
cryoglobulins from four of six patients and five of seven controls. 
showed only a weak reaction with one patient and no controls. 
Fibrinogen and ceruloplasmin did not precipitate lines of identity 
with any sera (Table 2). 
B. Absence of Circulating snRNP Immune Complexes from Sera of Four 
Patients with SLE. 
Lupus patients often possess antibodies against two extractible 
nuclear antigens, Sm and RNP (31). The molecular identity of their 
RNA has been established as the nucleoplasmic snRNA species U1 (RNP) 
and U1, U2, U4-6 (Sm) (31). Although antibodies to these snRNPs have 
been found in SLE sera, intact immune complexes have never been 
identified. Recently, with the cloning of the U1 gene a powerful 
technique to identify the presence of snRNP complexes has become 
available. 
Four patients with SLE donated 50ml of blood from which 25ml of 
serum was recovered. All patients were previously found to possess 
antibodies against Sm or RNP or both. Cryoglobulins were precipitated 
with 6% PEG and loaded onto a 10-40^ sucrose density gradient. After 
completion of the run, the gradient was fractionated and each fraction 
tested spectrophotometrically for its protein content. Three peaks 

30 
were identified (Figures 6, 7). The first peak (bottom of gradient) 
represents sedimented debris. The second is found at the 19S level 
and represents free serum proteins (77). Fractions representing the 
second peak were pooled and adsorbed to Pansorbin. Any RNA that was 
present was extracted with PCA and loaded onto a urea-acrylamide gel. 
Control snRNP immune complexes were prepared and the RNA extracted as 
described with the experimental samples. Likewise, ^2p iabeied RNA 
standards were also loaded. After completion of the gel run and 
transfer procedure, the Northern paper was hybridized with the U1 
probe. 
An autoradiograph visualizes lanes 5, 6 and 7 (Figure 8). Lanes 
5 and 6 represent control immune complexes and signify three things. 
The first is that RNA could not have been lost or somehow degraded 
during the extraction steps. The second is that the transfer 
procedure was performed properly. The fact that the radiolabeled RNA 
standards located in lane 7 are also visualized serves as a second 
control for this step. Lastly, visualizing a band in lanes 5 and 6 
indicates that hybridization must have taken place. Three reasons can 
explain these findings. The first is that the method used is not 
sensitive enough to visualize naturally occurring immune complexes. 
This explanation is unlikely since the Northern procedure can 
visualize as little as lOpg of RNA per band. The second reason is 
that the RNA in the complexes was degraded by ribonucleases (29,30). 
This is also unlikely since Sm is resistant to RNases and the 
isolation procedure was carried out rapidly and at low temperature. 
The third possibility is that circulating snRNP immune complexes are 




A. Composition of Cryoprecipitates 
In 1973, Creighton et al. reported that immune complexes can be 
precipitated by polyethylene glycol (83). Recently, Hardin described 
a group of reversibly cryoprecipitable non-immunoglobulin proteins 
which precipitate from normal sera treated with 3% PEG (77). 
Considered together, these immune complexes and serum proteins 
resemble the cryoglobulins first described by Lerner (59,60). 
This work found that a PEG cut of normal serum is 
electrophoretically identical in its protein composition to 
cryoglobulins precipitated in the cold. For the proteins tested, the 
two samples are also immunologically identical. Studies of 
cryoglobulins can thus be carried out using PEG cuts rather than 
proteins precipitated in the cold. One immediate benefit is the 
reduction in time needed to perform the isolation steps from three 
days to just a few hours. Using PEG cuts will allow experiments to be 
run which were previously difficult and costly to perform. Large 
quantities of serum are required to obtain usable amounts of protein, 
even from SLE patients who have relatively large quantities of 
cryoglobulins. PEG causes nearly complete precipitation so even a 
small amount of serum provides sufficient amounts of cryoprecipitates. 
When cryoglobulins from normal and lupus patients were 
electrophoretically compared, the band pattern showed that the protein 
composition of the samples is identical. The only noted difference 
was an increased concentration of proteins in the lupus samples. This 
result sheds some light on the mechanism of cryoprecipitation in SLE. 
First, it essentially rules out the possibility of disease specific 

32 
proteins as a cause of cryoglobulinemia. Since no new bands were 
visualized in the SLE samples, cryoprecipitation must be due to the 
increased concentration of one or more proteins normally present in 
the serum. Although immunoglobulin was one of the components found 
increased in concentration, it is unlikely that it is the predominant 
cause of increased precipitation. As Hardin and others have pointed 
out cryoprecipitation can occur in serum deficient in immune complexes 
(77,78). Also, removing immune complexes from PEG cuts does not 
eliminate the reversible cryoprecipitability of the remaining 
proteins. Thus, Levo's, Erickson's and Christian's theories on 
cryoprecipitability do not apply to SLE (62-64,68,69). There remain 
two likely causes of cryoprecipitation. The most likely candidate for 
a normal protein causing cryoprecipitation is fibronectin. 
Fibronectin reversibly binds fibrinogen in the cold to form complexes 
around which other proteins precipitate. Its removal from sera 
significantly decreases the amount of precipitate that will form (75- 
77). The other explanation is that cryoprecipitation is due to normal 
molecular interactions of proteins in a saturated solution resulting 
in precipitation in the cold. These two explanations are not mutually 
exclusive and most likely act in concert. Hopefully, future 
experiments will show the relative contribution of each mechanism. 
Although cryoprecipitation can occur without immune complexes 
being present, that cryoglobulinemia is intimately linked to an 
aberrant immune response is undeniable. Consequently, it is not 
surprising that this study found C^, and possibly to be present 
in cryoprecipitates. This evidence further extends our knowledge 
about the protein identity of cryoprecipitates. Future experiments may 
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want to determine the location of the various proteins in an 
acrylamide gel by using radiolabeled antisera. This would 
unambiguously identify which proteins are increased in concentration 
in lupus sera and thus further elucidate the mechanism of 
cryoprecipitation. 
B. Absence of Circulating snRNP Immune Complexes from Sera of Four 
Patients with SLE. 
As mentioned previously, lupus patients have antibodies which 
bind to snRNPs jin vitro and so are also thought to have the complexes 
in vivo. In the last part of this work, we set out to identify 
circulating snRNP immune complexes in the blood of lupus patients. 
The hybridization technique used is very sensitive and can detect less 
than lOpg of RNA per band (91). Controls were used at each step and 
were positive throughout. 
snRNP complexes were not visualized. One explanation is that they 
do not exist _in vivo. SLE patients produce a broad spectrum of 
antibodies. Although each is targeted against one particular antigen, 
they may cross react with an unrelated though antigenically similar 
compound. Thus, snRNPs may not be the in vivo target of these 
antibodies but rather represent a cross reaction jji vitro. However, 
this can only be proven by exclusion (by ruling out all other 
explanations) or by finding another antigen in lupus sera which also 
reacts with the same antibodies. 
A second explanation is that the techniques used were not 
sensitive enough to detect the immune complexes. In light of the 
sensitivity and specificity of the techniques used, this seems 
unlikely. However, it may be that while antibodies to snRNPs are 
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always present in the sera of some patients with SLE, the immune 
complexes themselves are only present during an acute phase of the 
disease. Once a patient gets over the acute phase, the immune 
complexes may be quickly cleared from the blood. Since blood samples 
were obtained during a quiescent phase, this may explain why no 
complexes were found. 
A third explanation is that RNA portion of the snRNPs was 
degraded by ribonucleases during the isolation steps. This is also 
unlikely since all steps were carried out rapidly and at either 0°C or 
4°C. Furthermore, snRNPs are relatively insensitive to attack by 
ribonucleases (29,30,47). The last explanation is that the immune 
complexes were not found due to a technical error. This can only be 
proven by further repeating the experiments. 
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32 Figure 1. Polyacrylamide gel electrophoresis of P-labeled 
nucleic acids from HeLa cells. Total cell sonicate (lane 
T). Bands In other lanes were obtained by immunopreclpita- 
tlon of cell extracts with patient antl-rRNA (lane R)» 
normal human serum (lane N), patient antl-La (lane La), 
patient antl-Sm (lane Sm), patient antl-RNP (lane RNP), 
patient anti-Ro (lane Ro), and patient antl-tRNA (lane 
tRNA). The bands labeled 5.8S and 5S are characteristic of 
rRNA. See text for the description of other bands. 
Figure 1. From Lerner, E.A., Lerner, M.R., Hardin, J.A., 
Janeway, C.A. Jr., and Steitz, J.A. Deciphering the mysteries of RNA- 








dsDNA 50-60 5 
ssDNA 50-60 20-25 
Histones 25-30 5 
Sm 25-30 5 
RNP 30-40 95-100 
La 10-15 5 
Ro 30-40 5 
PcNA 10 5 
Table 1. Specificities of ANAs found in SLE and in mixed 
connective tissue disease (MCTD). From Tan, E.M. Special antibodies 
for the study of systemic lupus erythematosus: An analysis. Arthritis 
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Antibody Well Cryoglobulins 
Figure 2. Diagram of a double immunodiffusion slide. 1% agarose 
in PBS was layered 1mm thick on a glass microscope slide. Six wells 
were punched out on both halves of the slide. The center well 
contained the antisera and the five surrounding wells contained 




Figure 3. Apparatus used to transfer RNA from a urea-acrylamide 
gel to Northern paper. Transfer is carried out overnight at room 
temperature. 

Standards PEG Cuts C ryog1obu1 ins 
Figure 4, Comparison of PEG cuts to cryoglobulins precipitated 
in the cold. Sera was obtained from three patients: A, B, C. Control 
lane had proteins of MW 94K, 67K, 43K, 30K, and 20K. 
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Figure 5. Comparison of protein precipitate from 1ml of SLE sera 
and 1ml of sera from healthy volunteers. Four patients and four 
volunteers were used and proteins were precipitated with PEG. Control 
lane contains proteins of MW 94K, 67K, 43K, 30K and 20K. 

HEALTHY CONTROLS SLE PATIENTS 
PEG CRYO 
Table 2. Above table shows the results of a double 
immunodiffusion experiment. Antisera against C3, C4, C5, fibrinogen, 
ceruloplasmin, IgG and whole serum was diffused against cryoglobulins 
from eight healthy controls and five SLE patients. Cryoglobulins from 
controls A-E were precipitated with PEG while controls F-H were 











Figure 6. 10-40$ sucrose density gradient of PEG cuts of SLE 
serum. Middle peak, centered around fraction 8, represents the immune 
complexes. Gradient was spun at 27K, at 4°C for 18 hours. 
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Figure 7. Acrylamide gel of peaks 1, 2, 3, and 4 which are 
centered around fractions 2, 8, 18, and 24, respectively, from the 10- 
40^ sucrose density gradient (Figure 6). Lane 5 contains protein 
standards of MW 94K, 67K, 43K, 30K and 20K. Lane 6 contains IgG and 
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Figure 8. Autoradiograph of Northern paper visualizes lanes 5, 
6, and 7. Lanes 1-4 were to contain snRNA from immune complexes of 
four SLE patients. No RNA was visualizd. Lanes 5 and 6 contained Sm 
and RNP control immune complexes, respectively. Lane 7 shows 
radiolabeled RNA standards. The fact that lanes 5-7 are visualized 
signifies that RNA extraction, electrophoresis, transfer and 
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